Showing 3621-3630 of 5910 results for "".
- Carl Zeiss Meditec Completes Acquisition of IanTECHhttps://modernod.com/news/carl-zeiss-meditec-completes-acquisition-of-iantech/2476242/Carl Zeiss Meditec has officially completed its acquisition of IanTECH, a privately held company focused on technology solutions for micro-interventional cataract surgery headquartered in Reno, Nevada. IanTECH is the maker of the miLOOP Lens Fragmentation Device, which is the first in a li
- First IC-8 Small Aperture IOL Implanted in the United Stateshttps://modernod.com/news/first-ic-8-small-aperture-iol-implanted-in-the-united-states/2476252/AcuFocus announced that the first US patient has been implanted with the IC-8 small aperture IOL as part of its pivotal study of the IC-8 lens in cataract patients. The company recently announced approval for an investigational device exemption (IDE) from the FDA to conduct the study. The
- Criminal Case Against James Mazzo Dismissedhttps://modernod.com/news/criminal-case-against-james-mazzo-dismissed/2476151/After a legal battle that spanned a decade, the insider trading criminal case against ophthalmic executive James Mazzo has come to an end. Late Thursday at the Ronald Reagan Federal Building in Santa Ana, California, federal prosecutors asked Judge Andrew Guilford to dismiss all criminal c
- Federal Trade Commission Penalizes Online Sellers for Violating Contact Lens Rule, Bans Them from Selling Lenses in Futurehttps://modernod.com/news/federal-trade-commission-penalizes-online-sellers-for-violating-contact-lens-rule-bans-them-from-selling-lenses-in-future/2476152/The Healthcare Alliance for Patient Safety released a statement following yesterday’s announcement from the Federal Trade Commission (FTC)
- Oncobiologics Changes Name to Outlook Therapeutics; Announces Next Steps for ONS-5010 Clinical Strategyhttps://modernod.com/news/oncobiologics-changes-name-to-outlook-therapeutics-announces-next-steps-for-ons-5010-clinical-strategy/2476161/Oncobiologics announced several key corporate events that enhance the company’s ability to advance the development of its lead product candidate, ONS-5010, a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration (AMD). These events are in c
- Study: Ocular Technology Provides Early Detection of Alzheimer’s Diseasehttps://modernod.com/news/study-ocular-technology-provides-early-detection-of-alzheimers-disease/2479626/A recent study from JAMA Ophthalmology finds that a specific type of noninvasive eye testing procedure may help assess risk for Alzheimer’s disease. One in 10 Americans over the age 65 has Alzheimer’s, while one-third over the age of 85 have the disease. Fortunately, res
- Alcon Launches Alcon Retina Fellows Institute to Support Future Leaders of Ophthalmologyhttps://modernod.com/news/alcon-launches-alcon-retina-fellows-institute-to-support-future-leaders-of-ophthalmology/2479630/Alcon announced it is expanding its support of eye care professionals through the launch of a one-of-a-kind training opportunity, the Alcon Retina Fellows Institute. The unique educational offering supports retina fellows during a weekend-long training at the Alcon Experience Center in Fort Worth
- New Data Indicate that EyeMax Mono Offers Significant Improvement in Visual Function in Dry AMD Patientshttps://modernod.com/news/new-data-indicate-that-eyemax-mono-offers-significant-improvement-in-visual-function-in-dry-amd-patients/2479640/LEH Pharma announced new data published in the Journal of Refractive Surgery, suggesting that EyeMax Mono offers benefits in terms of visual function for people with dry age-related macular degeneration (AMD). EyeMax Mono is an IOL specifically designed to deliver improved visual outcome
- AsclepiX Therapeutics Raises $5 Million to Advance Therapies in AMD and DMEhttps://modernod.com/news/asclepix-therapeutics-raises-5-million-to-advance-therapies-in-amd-and-dme/2479676/AsclepiX Therapeutics announced that it has raised $5 million in convertible note funding to accelerate development of AXT107, its treatment for two leading causes of adult blindness: diabetic macular edema (DME) and wet age-related macular degeneration (AMD). These diseases are now treated with
- Bausch’s Papa Says ‘Transformation on Track’ as Debt Paydown Continueshttps://modernod.com/news/bauschs-papa-says-transformation-on-track-as-debt-paydown-continues/2479690/The turnaround at Quebec-based Bausch Health Cos. appeared to take another step forward Tuesday, after the company reported positive organic growth for the third quarter, sending shares up more than five percent in Toronto, according to a Financial Post